CPT® Code 87906

The CPT® Code 87906 refers to the process of conducting an infectious agent genotype analysis specifically for HIV-1, focusing on regions other than those typically associated with reverse transcriptase and protease inhibitors. This analysis is crucial for identifying mutations within the HIV-1 genome that may lead to resistance against certain antiretroviral therapies, particularly those targeting the integrase enzyme, which is essential for the viral replication process. The integrase gene mutations can indicate resistance to integrase inhibitors such as raltegravir and elvitegravir, which are vital components of treatment regimens for HIV infection. HIV, or human immunodeficiency virus, is a retrovirus that primarily attacks the immune system by targeting CD4 T cells, which are critical for immune response. The progression of untreated HIV can lead to acquired immunodeficiency syndrome (AIDS), a severe condition characterized by a significantly weakened immune system. Given the high replication rate of HIV and the propensity for mutations during replication, initial treatment often involves highly active antiretroviral therapy (HAART), which combines multiple drugs with different mechanisms to effectively reduce viral load and minimize the risk of resistance. When initial therapies fail, performing a genotype analysis becomes essential to tailor subsequent treatment strategies. This complex test utilizes a blood sample to assess the presence of specific nucleic acid sequences associated with drug resistance, employing techniques such as polymerase chain reaction (PCR) for amplification, purification, and comparative analysis against known resistance profiles. The insights gained from this analysis are instrumental in formulating a more effective drug regimen aimed at controlling the HIV infection and improving patient outcomes.